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Alzheimer’s disease (AD) is characterized by widespread degeneration of cholinergic neurons, particularly
in the basal forebrain. However, the pattern of these deficits and relationship with known brain networks
is unknown. In this study, we sought to clarify this and used 123I-5-iodo-3-[2(S)-2-azetidinylmethoxy]
pyridine (1235IA-85380) single photon emission computed tomography to investigate spatial covariance of
a4b2 nicotinic acetylcholine receptors in AD and healthy controls. Thirteen AD and 16 controls underwent
1235IA-85380 and regional cerebral blood flow (99mTc-exametazime) single photon emission computed
tomography scanning. We applied voxel principal component (PC) analysis, generating series of principal
component images representing common intercorrelated voxels across subjects. Linear regression gener-
ated specific a4b2 and regional cerebral blood flow covariance patterns that differentiated AD from con-
trols. The a4b2 pattern showed relative decreased uptake in numerous brain regions implicating several
networks including default mode, salience, and Papez hubs. Thus, as well as basal forebrain and brainstem
cholinergic system dysfunction, cholinergic deficits mediated through nicotinic acetylcholine receptors
could be evident within key networks in AD. These findings may be important for the pathophysiology of
AD and its associated cognitive and behavioral phenotypes.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
One of the pathological characteristics of Alzheimer’s disease
(AD) is degeneration of cholinergic neurons of the basal forebrain
(Davies and Maloney, 1976; Whitehouse et al., 1982) and acetyl-
choline is central to a myriad of brain functions including learning
and memory (Hasselmo, 2006), attention (Himmelheber et al.,
2000; Klinkenberg et al., 2011), and the sleep-wake cycle (Lee
et al., 2005). As memory is a key cognitive domain that is
impaired in AD, the cholinergic hypothesis was proposed as a key
pathophysiological mechanism (Bartus et al., 1982). This remains at
the heart of symptomatic management of AD, with widespread use
of acetylcholinesterase inhibitors as principal first-line treatment,ence, Newcastle University,
e NE4 5PL, UK. Tel.: þ44 191
).
Inc. This is an open access articledespite the variability in response and often limited benefits
(Zemek et al., 2014). It is, therefore, important to continue to
interrogate the role of cholinergic networks in AD in order to
improve our understanding of these systems and to drive devel-
opment of optimal therapeutic interventions in this condition.
Cholinergic neurotransmission in the brain is mediated by ion-
otropic nicotinic acetylcholine receptors (nAChRs) and metabo-
tropic muscarinic receptors (mAChRs), both of which have been
implicated in the cognitive deficits in AD (Petersen,1977; Sarter and
Paolone, 2011). The nAChR, which is the focus of this study, consists
of 8a (a2ea7, a9, and a10) and 3b (b2eb4) subunits. These may
assemble in different combinations to generate nAChR subtypes
with varying electrophysiological properties and brain distribution
(Albuquerque et al., 2009; Lindstrom et al., 1995), with the most
abundant varieties in humans being a4b2 and a7.
There is now increasing evidence that decreased network
connectivity is associated with aging and that this process is
accelerated in AD, with specific systems such as the default mode
network (DMN) particularly affected (Dennis and Thompson,under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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contribute to the AD symptomatology including memory changes
(He et al., 2009; Sperling et al., 2010) and neuropsychiatric fea-
tures (Rosenberg et al., 2015). However, what is less appreciated is
the role the cholinergic system exerts on some of these key
functional networks in AD. One way to examine network con-
nectivity is by spatial covariance analysis. In AD, such procedures
have previously been investigated with glucose metabolism
positron emission tomography and perfusion single photon
emission computed tomography (SPECT) imaging (Habeck et al.,
2008; Johnson et al., 1998; Scarmeas et al., 2004). Indeed, we
recently successfully applied the technique to 123I-iodo-quinucli-
dinyl-benzilate SPECT in AD, deriving an M1/M4 mAChR spatial
covariance pattern (SCP) that characterized the receptor changes
to cholinergic depletion (Colloby et al., 2015).
In the present study, we applied spatial covariance analysis to
123I-5IA-85380 SPECT scans, a ligand with high affinity for a4b2
nAChRs, in a sample of AD patients and healthy similar aged con-
trols (O’Brien et al., 2007), to investigate disease-related a4b2
nAChR cholinergic networks. Since interpretation of 123I-5IA-85380
images in isolation is difficult due to uncertainty over the effects of
cell loss, we also studied the corresponding perfusion resting-state
networks.2. Methods
2.1. Subjects
The sample consisted of 29 nonsmoking (>10 years) subjects (13
AD and 16 healthy elderly controls). Patients with AD were
recruited from a community-dwelling population following referral
to local old-age psychiatry services. Normal controls were recruited
from friends and spouses of patients included in this and other
research studies. All subjects underwent 123I-5IA-85380 and 99mTc-
exametazime SPECT scanning, with scans undertaken within
3 months of each other. The study was approved by the Newcastle,
North Tyneside, and Northumberland local research ethics com-
mittee and the UK Department of Health’s Administration of
Radioactive Substances Advisory Committee (ARSAC). All partici-
pants and/or nearest relative (for patients who lacked capacity)
gave informed written consent.2.2. Assessments and diagnosis
Subjects underwent physical, neurological, and neuropsychi-
atric assessments, including mental state, history, physical exami-
nation, and for patients, blood screenwith B12 and folate levels. The
study battery administered included the Mini-Mental State Exam-
ination (MMSE) (Folstein et al., 1975), Neuropsychiatric Inventory
(Cummings et al., 1994), Cambridge Cognitive Examination (CAM-
COG) (Roth et al., 1986) with memory and executive function sub-
scales (CAMCOGmemory, CAMCOGexec).
Diagnosis was made by consensus between 2 experienced cli-
nicians using the National Institute of Neurological and Commu-
nicative Disorders and Stroke/Alzheimer’s Disease and Related
Disorders Association (NINCDS/ADRDA) criteria for AD (McKhann
et al., 1984). All AD subjects met criteria for probable AD. Controls
had no signs or symptoms of cognitive disturbance and did not
meet criteria for mild cognitive impairment, and all scored within
the normal range of cognitive tests; 27 on MMSE, 90 on CAM-
COG, and>2 standard deviations (SDs) above cutoff scores denoting
cognitive impairment. Clinicopathological diagnosis was confirmed
for 3 cases that subsequently died (1 control, 2 AD).2.3. Radiochemistry
Radiosynthesis of 123I-5IA-85380 was produced form the cor-
responding stanyl precursor, 5-SnBu3-A85380, by electrophilic
iododestanylation and performed according to details previously
described (O’Brien et al., 2007).
2.4. Acquisition
Subjects were scanned with a triple-headed rotating gamma
camera (Picker 3000XP), 2 hours post injection of 185 MBq of 123I-
5IA-85380 using a previously reported imaging protocol (O’Brien
et al., 2007). Within 3 months of 123I-5IA-85380 scanning, all sub-
jects underwent 99mTc-exametazime regional cerebral blood flow
(rCBF) SPECT in accordance with methods described in an earlier
study (Colloby et al., 2008).
2.5. Spatial preprocessing
All SPECT scans were spatially normalized to match, as appro-
priate, a 123I-5IA-85380 or 99mTc-exametazime SPECT template in
standard stereotactic space using linear image registration software
(FLIRT: http://www.fmrib.ox.ac.uk/fsl/flirt/index.html). Generation of
the template images has been described (Colloby et al., 2008; O’Brien
et al., 2007). The spatially transformed images were then smoothed
with a 10-mm full width at half maximum 3D Gaussian filter.
2.6. Spatial covariance analysis
Principal component (PC) analysis was applied on a voxel basis to
all processed 123I-5IA-85380 SPECT images using covariance analysis
software (http://www.nitrc.org/projects/gcva_pca/) (Habeck et al.,
2005), producing a series of PC images. For each PC image, voxels
had either positive or negative weights that represent the sign and
strength of covariance between voxels. In this study, voxels with
positive and negative weights were viewed as concurrently pre-
served/increased and decreased a4b2 binding, respectively. The
extent towhich an individual expressed thePC imagewasbywayof a
subject scaling factor (SSF) for that PC, calculated by superimposing
the PC image onto an individual’s processed 123I-5IA-85380 scan by
computation of a “dot product,”which involves imagemultiplication
on a voxel basis followed by summation of the products generating a
score.HigherSSF scores foran individual for thatPC image represents
greater increasedbinding invoxelswithpositiveweights andgreater
concurrent decreased binding in voxels with negative weights. To
identify the 123I-5IA-85380 SCP that distinguished AD from controls,
each individual SSF was entered into a linear regression model as
explanatory variables with group as the dependent parameter.
Akaike’s information criteria (AICs) determined how many PCs
should be included to reach optimal bias-variance trade-off
(Burnham and Anderson, 2002). Seven PCs (1, 3, 4, 5, 6, 7,10) yielded
the lowestAICvalueandwereusedtoderive theSCP5IA. Thedegree to
which each subject expressed the SCP5IA was by way of the SSF5IA.
The same approach was applied to the 99mTc-exametazime
SPECT scans. Therefore, positive and negative weights were inter-
preted as concurrent increased and decreased rCBF, respectively.
Five PCs (1, 2, 3, 4, 12) yielded the lowest AIC value and were used to
generate the SCPrCBF that best separated AD from controls, while
each subject expressed the SCPrCBF by their SSFrCBF.
Stability and reliability of the SCPs were assessed by bootstrap
resampling (1000 iterations), to identify areas that contributed to
the patterns with high confidence. This transforms the voxel
weights of each SCP into Z maps, computed as the ratio of voxel
weight and bootstrap standard deviation. The Z-statistic follows
roughly a standard normal distributionwhere a one-tailed p  0.05
Table 1
Demographic, clinical, and neuropsychological information for individuals studied
with123I-5IA-85380 SPECT
Control AD Statistic, p value
N 16 13
Gender (male:female) 10:6 6:7 c2(1) ¼ 0.8, p ¼ 0.4
Age 75.4  4.5 79.7  6.6 F1,27 [ 4.5, p[ 0.04
MMSE 28.8  1.0 17.7  5.2 F1,27 [ 69.8, p < 0.001
CAMCOG 97.8  3.8 59.8  19.4 F1,27 [ 59.0, p < 0.001
CAMCOGmemory 24.0  1.8 10.2  5.9 F1,27 [ 79.0, p < 0.001
CAMCOGexec 23.3  3.1 10.8  4.0 F1,27 [ 90.5, p < 0.001
NPI n/a 12.2  12.3
Medications
ChEIs 0 2
Data are expressed as mean  1 SD.
Bold text denotes significant differences.
Key: AD, Alzheimer’s disease; CAMCOG, Cambridge Cognitive Examination;
CAMCOGexec, executive function component of CAMCOG; CAMCOGmemory, memory
component of CAMCOG; ChEIs, cholinesterase inhibitors; MMSE, Mini-Mental State
Examination; n/a, not applicable; NPI, Neuropsychiatric Inventory; SD, standard
deviation.
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labeling of the Z maps was performed using the image visualization
software “FSLView” (http://fsl.fmrib.ox.ac.uk/fsl/fslview/), which
contains various anatomical brain atlases from which the labels
were reported from.Fig. 1. a4b2 nicotinic acetylcholine receptor spatial covariance pattern in AD (jZj  1.64, p  0
superimposed upon the 123I-5IA-85380 SPECT template distinguishing AD from controls. R
respectively. (C) Distribution of SSF5IA scores in controls (n¼ 16) and AD (n¼ 13) (***p< 0.001)
receptor; P, posterior; R, right; SSF, subject scaling factor. (For interpretation of the references2.7. Statistical analyses
Continuous variables were tested for normality using visual in-
spection of histograms and Shapiro-Wilk test. Demographic, clin-
ical, and imaging measures were assessed, where applicable, using
parametric (analysis of variance) and nonparametric c2 tests. Cor-
relations were performed using Pearson’s r coefficients. Statistical
tests were interpreted as significant if p  0.05. Data analysis used
the Statistical Package for Social Sciences software (SPSS version
22.0, http://www-01.ibm.com/software/analytics/spss/products/
statistics/).3. Results
3.1. Subject demographics and clinical characteristics
Patient demographic and clinical characteristics are reported in
Table 1. AD subjects and controls were similar with respect to
gender, although there was a small difference in age with AD pa-
tients being slightly older than controls. As expected, AD subjects
were impaired on all cognitive measures compared to controls (p <
0.001). Two patients were receiving cholinesterase treatment
(donepezil, standard daily clinical dose 10 mg) (for >3 months) at
the time of the study..05). Orthogonal (A) and rendered (B) views of the a4b2 nAChR spatial covariance pattern
ed and blue regions depict relative increased and/or preserved and decreased activity,
. Abbreviations: A, anterior; AD, Alzheimer’s disease; L, left; nAChR, nicotinic acetylcholine
to color in this figure legend, the reader is referred to the Web version of this article.)
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The a4b2 nAChR voxel SCP5IA that distinguished AD from
controls is shown in Fig. 1A and B. SSF5IA scores, representing the
extent to which subjects expressed the topography, were higher in
AD than controls (mean  SD; AD ¼ 9.3  2.0, controls ¼ 2.6  1.4,
t27¼ 10.8, p< 0.001, Fig. 1C). The patternwas mainly characterized
by relative decreases in a4b2 binding (blue) in basal forebrain,
pedunculopontine, thalamus, limbic, parietal, and frontal regions
together with relative preserved or increased binding (red) in
midbrain, pallidum, cerebellum, occipital, and pre/post central
gyri. Table 2 depicts details of specific regions contributing to the
a4b2 disease-related pattern with high confidence (jZj  1.64, p 
0.05).
The associated rCBF SCPrCBF that differentiated AD from controls
is depicted in Fig. 2A and B, where SSFrCBF scores differed between
groups (mean SD; AD¼ 10.0 1.9, controls¼ 3.2 1.5, t27¼ 10.6,
p < 0.001, Fig. 2C). The pattern mainly comprised of relative
decreased rCBF (blue) in thalamus, cingulate, parietal, and pre-
frontal areas with relative increases (red) in cerebellum, lentiform
nucleus, lingual gyrus, and precentral regions. Table 3 depicts
details of specific regions significantly contributing to the rCBF
diseaseerelated pattern (jZj  1.64, p  0.05).Table 2
Regions contributing to the a4b2 diseaseerelated pattern with high confidence (jZj
 1.64, p  0.05) in AD
Hemisphere MNI coordinates Region Z score
4, 29, 28 Pedunculopontine nucleus 2.2
L 8, 8, 12 Nucleus accumbens 1.9
R 12, 8, 12 Nucleus accumbens 2.0
L 24, 12, 24 Hippocampus 2.3
R 28, 12, 20 Hippocampus 1.7
L 20, 4, 20 Amygdala 1.9
R 28, 0, 20 Amygdala 1.8
L 16, 16, 20 Orbitofrontal cortex 1.9
R 24, 12, 20 Orbitofrontal cortex 2.3
L 0, 36, 16 Medial frontal cortex 2.1
R 4, 36,16 Medial frontal cortex 2.0
L 28, 20, 8 Insula 1.7
R 44, 12, 4 Insula 2.5
L 52, 24, 4 Inferior frontal gyrus 2.0
R 56, 16, 4 Inferior frontal gyrus 2.2
L 8, 20, 16 Thalamus 2.5
R 12, 20, 16 Thalamus 2.9
L 4, 8, 36 Anterior cingulate 3.3
R 4, 32, 16 Anterior cingulate 2.3
L 0, 44, 32 Posterior cingulate 2.0
R 4, 32, 32 Posterior cingulate 1.8
L 48, 48, 44 Inferior parietal 2.2
R 52, 60, 48 Inferior parietal 1.7
L 4, 72, 52 Precuneus 1.9
R 4, 48, 64 Precuneus 1.9
R 16, 8, 8 Putamen 1.9
L 12, 60, 36 Posterior cerebellum 2.4
R 20, 56, 36 Posterior cerebellum 2.8
L 12, 60, 24 Anterior cerebellum 2.3
R 20, 56, 24 Anterior cerebellum 2.6
L 12, 16, 10 Midbrain 2.0
R 18, 18, 10 Midbrain 2.0
L 20, 12, 0 Pallidum 2.1
R 24, 12, 0 Pallidum 2.0
L 40, 72, 12 Middle occipital gyrus 2.5
R 36, 84, 16 Middle occipital gyrus 2.9
L 12, 88, 16 Cuneus 2.8
R 20, 84, 16 Cuneus 2.7
L 48, 16, 32 Postcentral gyrus 2.2
R 52, 12, 32 Postcentral gyrus 2.5
L 44, 4, 36 Precentral gyrus 2.0
R 52, 4, 36 Precentral gyrus 1.8
Key: AD, Alzheimer’s disease; L, left; MNI, Montreal Neurological Institute; R, right.Relationship between SCP expressions and age, MMSE,
CAMCOG, CAMCOGmemory, and CAMCOGexec were investigated in
AD. Trends were observed in CAMCOG (r ¼ 0.52, p ¼ 0.03),
CAMCOGmemory (r ¼ 0.51, p ¼ 0.04), and MMSE (r ¼ 0.54, p ¼
0.03) with SSF5IA but not age and CAMCOGexec (jrj  0.37, p 
0.11). For SSFrCBF, CAMCOG (r ¼ 0.47, p ¼ 0.05) and MMSE
(r ¼ 0.52, p ¼ 0.04) correlated, while for all other measures (jrj
 0.42, p  0.08).
It was evident that there was some degree of similarity be-
tween the nicotinic and rCBF patterns, supported by the signifi-
cant correlations that were observed between the SSF5IA and
SSFrCBF scores in controls (r¼ 0.61, p¼ 0.006) and AD (r¼ 0.74, p¼
0.002). We, therefore, sought to explore in a descriptive sense,
regions that differed between the 2 patterns by subtraction of
their respective bootstrapped spatial covariance Z maps. Fig. 3
shows the difference in image (SCP5IA  SCPrCBF), where the blue
and red regions represent (Z5IA  ZrCBF) 2.0 and (Z5IA  ZrCBF) 
2.0, respectively. The difference image showed deviations in
pedunculopontine nucleus, insula, anterior cingulate, putamen,
thalamus, and frontal regions (blue) along with precuneus, lateral
occipital, temporal, and parietal areas (red). Blue regions charac-
terize greater negative weights in the nicotinic pattern relative to
rCBF or where voxel weightings are of opposite sign
(nicotinic ve, rCBF þve), whereas red regions describe greater
positive weights in the nicotinic pattern relative to rCBF or where
voxel weightings are of opposite sign (nicotinic þve, rCBF ve).
Table 4 presents details of specific regions contributing to the
difference pattern.
4. Discussion
We undertook a multivariate network perspective of 123I-5IA-
85380 SPECT, a a4b2 nAChR ligand in AD. We derived disease-
related a4b2 nAChR and rCBF patterns of spatial covariance,
which implies the presence of several dysfunctional cholinergic
and perfusion networks in AD. These findings represent the first
attempt to differentiate AD from controls through spatial covari-
ance analysis of cholinergic nicotinic receptor activity and/or
availability, and follow our multivariate assessment of M1/M4
mAChR binding in AD (Colloby et al., 2015).
The nAChR covariance pattern comprised of decreased and
preserved and/or increased activity in a number of concomitant
brain areas. The covariant negative-weighted pattern converged
on various subcortical and neocortical regions, implicating a
number of cholinergic networks. In particular, the basal fore-
braineneocortex and hippocampus system appeared to be
affected, and this network is widely recognized as a significant
contributor to memory and learning processes. The brainstem
system which may mediate the sleep-wake cycle also appears to
be involved with relative reduced uptake in pedunculopontine
nucleus and thalamus. This observation is in keeping with clinical
observations that sleep-wake disturbances are highly prevalent
and often a disabling feature in AD (Lim et al., 2014), although in
the present study we did not have data on the nature or severity
of any sleep disturbances in our patient group to clarify any
specific clinical relationships. We also observed a relative
decreased binding which mapped onto DMN hubs, namely,
medial prefrontal, posterior cingulate, precuneus, and inferior
parietal. This network is active during rest and deactivates during
goal-directed behaviors (Raichle et al., 2001), where evidence has
shown reduced DMN activity in AD (Greicius et al., 2004; Simic
et al., 2014) and its contribution to cognitive decline (Seeley
et al., 2009). One study reported convergences of amyloid
deposition, metabolic disruption, and atrophy of the DMN in AD
(Buckner et al., 2005), suggesting that the relative decreased
Fig. 2. Regional cerebral blood flow spatial covariance pattern in AD (jZj  1.64, p  0.05). Orthogonal (A) and rendered (B) views of the rCBF spatial covariance pattern super-
imposed upon the 99mTc-exametazime SPECT template distinguishing AD from controls. Red and blue regions depict relative increased and decreased activity respectively. (C)
Distribution of SSFrCBF scores in controls (n ¼ 16) and AD (n ¼ 13) (***p < 0.001). Abbreviations: A, anterior; AD, Alzheimer’s disease; L, left; P, posterior; R, right; rCBF, regional
cerebral blood flow; SSF, subject scaling factor. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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pathological and/or functional deficits, although an element of
concomitant DMN cholinergic dysfunction cannot be excluded.
Reduced DMN activity of nAChRs was consistent with our pre-
vious findings of reduced M1/M4 mAChR expressions within
similar regions (Colloby et al., 2015), highlighting the potential
role of both types of receptors in AD and that the cholinergic
system may have a more fundamental role in the normal
functioning of the DMN. Other mappings onto established
resting-state networks, included the anterior insula and anterior
cingulate, which are key nodes of the “salience network,” for
initiation of cognitive control and switching networks to aid ac-
cess to working memory and attention resources (Menon and
Uddin, 2010; Seeley et al., 2007). Networks involving the insula
have also been shown to play a role in episodic memory (Xie
et al., 2012). Furthermore, regions also mapped onto the Papez
circuit, a limbic network incorporating the thalamus, hippocam-
pus, and cingulate cortex (Papez, 1937). Its function lies in
emotional processing and memory, where numerous studies have
demonstrated its dysfunction and atrophy in AD (Allen et al.,
2007; Jones et al., 2006; Smith, 2002).
The associated rCBF pattern largely comprised of relative de-
creases in thalamus, cingulate, parietal, and prefrontal areas withrelative increases in cerebellum, lentiform nucleus, lingual gyrus,
and precentral regions, indicating impairment in a number of
functional networks. Regions that were concomitantly reduced
appear to involve hubs of the DMN and frontoparietal attention
(inferior parietal, dorsolateral prefrontal cortex) networks
(Markett et al., 2014); the latter finding chimes with a recent
study depicting dorsal and ventral attention systems dysfunction
in AD and amnestic mild cognitive impairment (Zhang et al.,
2015). The covariant pattern was also broadly consistent to
previous spatial covariance studies in AD using H215O positron
emission tomography (Scarmeas et al., 2004) and arterial spin
labeling perfusion magnetic resonance imaging (Asllani et al.,
2008). Differences in results between these studies were likely
attributed to variations in image modality and/or in AD
populations.
As an exploratory analysis, we examined correlations between
the cholinergic and perfusion covariance pattern expressions and
measures of cognition in AD. Although results were not corrected
for multiple tests, negative trends were observed with CAMCOG
and MMSE scores, suggesting the cholinergic and/or perfusion
patterns and the various networks they represented were simi-
larly related to global cognition and/or dementia severity.
Memory scores (CAMCOGmemory) only appeared to be associated
Table 3
Regions contributing to the corresponding rCBF pattern with high confidence (jZj 
1.64, p  0.05) in AD
Hemisphere MNI coordinates Region Z score
L 60, 40, 0 Middle temporal gyrus 1.9
R 68, 32, 16 Middle temporal gyrus 1.9
L 12, 28, 12 Thalamus 2.4
R 16, 28, 12 Thalamus 2.3
L 4, 48, 20 Posterior cingulate 2.2
R 4, 48, 28 Posterior cingulate 2.6
L 0, 20, 28 Anterior cingulate 2.2
R 4, 20, 28 Anterior cingulate 2.8
L 0, 56, 36 Precuneus 4.0
R 4, 60, 32 Precuneus 3.9
L 40, 64, 44 Inferior parietal 2.4
R 48, 64, 44 Inferior parietal 2.9
L 36, 20, 52 Middle frontal gyrus 2.1
R 32, 32, 44 Middle frontal gyrus 1.7
L 24, 28, 52 Superior frontal gyrus 2.2
L 16, 16, 24 Inferior frontal gyrus 1.9
L 16, 64, 36 Posterior cerebellum 4.2
R 24, 64, 36 Posterior cerebellum 3.8
L 16 64, 28 Anterior cerebellum 3.2
R 24, 64, 28 Anterior cerebellum 3.8
L 20, 16, 8 Putamen 2.2
R 24, 8, 4 Putamen 1.7
L 20, 4, 4 Pallidum 2.1
R 24, 12, 0 Pallidum 1.8
L 56, 0, 24 Precentral gyrus 2.2
R 60, 4, 24 Precentral gyrus 1.8
L 16, 48, 4 Medial frontal gyrus 2.5
R 20, 44, 4 Medial frontal gyrus 2.3
L 20, 56, 12 Lingual gyrus 2.0
R 20, 56, 12 Lingual gyrus 2.0
Key: AD, Alzheimer’s disease; L, left; MNI, Montreal Neurological Institute; R, right;
rCBF, regional cerebral blood flow.
Fig. 3. Difference image between the nicotinic and regional cerebral blood flow spatial cov
template. Red and blue regions represent (Z5IA  ZrCBF)  2.0 and (Z5IA  ZrCBF)  2.0, resp
covariance pattern. (For interpretation of the references to color in this figure legend, the r
S.J. Colloby et al. / Neurobiology of Aging 47 (2016) 83e9088with the cholinergic pattern which is not unexpected given
the observed deficits to spatial networks involving the medial
temporal lobe structures, and the putative role of acetylcholine
on learning and memory (Hasselmo, 2006; McGaughy et al.,
2000), as well as the established therapeutic efficacy of cholin-
esterase inhibitors in ameliorating cognitive symptoms in AD
(Zemek et al., 2014). Although our AD group was relatively
small, these results highlight that a larger-scale covariance
study may be useful to investigate specific correlates between
the clinical phenotype of AD and cholinergic network
dysfunction.
Although we used stratified bootstrap resampling to verify the
stability and reliability of the SCPs, the results were nonetheless
obtained from small samples and as a consequence may not be
generalizable and as such were a major drawback of this study.
Another study limitation was a minority of autopsy-confirmed
diagnoses and a relatively moderate demented patient group. It
was also difficult to establish whether the observed cholinergic
networks were attributed exclusively to changes in nicotinic re-
ceptor expression or to some extent by the functional rCBF
changes. Although descriptive and not rigorously inferential, we
investigated differences between the nicotinic and rCBF patterns
in order to identify areas of relative variation. The deviation map
suggests that brainstem system and salience networks were
perhaps more associated with nicotinic receptor expression,
whereas for DMN and Papez circuits suggest that this was less
clear. Receptor availability and rCBF were also influenced by at-
rophy and partial volume effects, so both types of scans were likely
to be equally affected by neural degeneration. Thus, common re-
gions of relative decreased uptake that are susceptible to AD pa-
thology may indicate atrophic effects rather than receptor or
functional changes. In addition, although there was a small age
difference between the groups, there were no significantariance patterns displayed axially and superimposed upon the 123I-5IA-85380 SPECT
ectively. Abbreviations: L, left; R, right; rCBF, regional cerebral blood flow; SCP, spatial
eader is referred to the Web version of this article.)
Table 4
Regions (jZ5IA  ZrCBFj  2.0) contributing to the difference in image (SCP5IA 
SCPrCBF)
Hemisphere MNI coordinates Region Z5IA  ZrCBF
8, 28, 28 Pedunculopontine nucleus 3.2
R 4, 60, 36 Vermis cerebellum 3.1
R 28, 68, 36 Posterior cerebellum 2.4
L 24, 64, 36 Posterior cerebellum 3.3
R 40, 0, 4 Insula 2.5
L 32, 24, 0 Insula 2.1
R 24, 16, 8 Putamen 3.7
L 20, 16, 8 Putamen 3.6
R 4, 8, 32 Anterior cingulate 2.8
L 0, 4, 36 Anterior cingulate 2.9
R 28, 20, 12 Orbitofrontal cortex 3.2
L 28, 8, 16 Amygdala 2.8
L 0, 24, 12 Subcallosal cortex 2.6
L 0, 44, 12 Medial frontal cortex 2.3
L 16, 4, 0 Pallidum 2.1
L 16, 24, 4 Thalamus 2.4
L 52, 32, 8 Inferior frontal gyrus 3.1
L 8, 36, 28 Paracingulate gyrus 2.5
L 20, 20, 64 Precentral gyrus 2.7
L 0, 60, 32 Precuneus 2.7
R 8, 56, 32 Precuneus 3.1
L 44 68, 16 Lateral occipital cortex 2.4
R 48, 64, 20 Lateral occipital cortex 2.2
R 56, 44, 16 Inferior temporal gyrus 2.2
R 52, 16, 12 Temporal pole 2.6
R 60, 52, 16 Angular gyrus 2.7
R 36, 60, 48 Superior parietal lobe 3.5
Key: L, left; MNI, Montreal Neurological Institute; R, right; rCBF, regional cerebral
blood flow; SCP, spatial covariance pattern.
S.J. Colloby et al. / Neurobiology of Aging 47 (2016) 83e90 89correlations between age and the nicotinic and rCBF subject scores
in controls or AD and therefore, unlikely to affect the discriminant
patterns. Strengths of this study were in examining AD patients
that were mainly free from any cholinergic medications as well as
having both nicotinic and perfusion SPECT scans available for all
subjects.
5. Conclusions
The multivariate perspective provides further insights into the
pathophysiological changes in AD. The SCP not only suggests basal
and brainstem cholinergic system deficits, but DMN, salience and
Papez cholinergic circuits may also be vulnerable, and that the
cholinergic system might have a more fundamental role in the
normal functioning of these networks in AD. Future studies could
examine the cholinergic network profiles that are associated with
positive treatment outcomes from therapies aimed at improving
cholinergic neurotransmission.
Disclosure statement
Dr Colloby, Dr Field, and Professor Wyper report no disclosures.
Professor O’Brien has been a consultant for GE Healthcare, Lilly,
Bayer Healthcare, TauRx, and Nutricia and has received honoraria
for talks from GE Healthcare, Lilly, and Novartis. Dr Taylor has been
a consultant of Lundbeck and received honoraria for talks from GE
Healthcare and Flynn pharmaceuticals.
Acknowledgements
The authors thank the Alzheimer’s Society, the Newcastle
Healthcare Charity, theMedical Research Council UK (grant number
G9817682), the National Institute for Health Research (NIHR)
for Public Benefit, Wellcome Trust (WT088441MA Fellowshipfunding John-Paul Taylor), NIHR Dementia Biomedical Research
Unit at Cambridge University Hospitals NHS Foundation Trust, the
University of Cambridge, The NIHR Newcastle Biomedical Research
Centre in Ageing and Chronic Disease, and Biomedical Research
Unit in Lewy Body Dementia based at Newcastle upon Tyne
Hospitals NHS Foundation Trust and Newcastle University. The
authors thank staff at the Regional Medical Physics Department,
Department of Nuclear Medicine, Newcastle General Hospital
for undertaking SPECT scanning, and all members of the clinical
research team who helped with patient recruitment and
assessment.References
Albuquerque, E.X., Pereira, E.F., Alkondon, M., Rogers, S.W., 2009. Mammalian
nicotinic acetylcholine receptors: from structure to function. Physiol. Rev. 89,
73e120.
Allen, G., Barnard, H., McColl, R., Hester, A.L., Fields, J.A., Weiner, M.F., Ringe, W.K.,
Lipton, A.M., Brooker, M., McDonald, E., Rubin, C.D., Cullum, C.M., 2007. Reduced
hippocampal functional connectivity in Alzheimer disease. Arch. Neurol. 64,
1482e1487.
Asllani, I., Habeck, C., Scarmeas, N., Borogovac, A., Brown, T.R., Stern, Y., 2008.
Multivariate and univariate analysis of continuous arterial spin labeling perfu-
sion MRI in Alzheimer’s disease. J. Cereb. Blood Flow Metab. 28, 725e736.
Bartus, R.T., Dean 3rd, R.L., Beer, B., Lippa, A.S., 1982. The cholinergic hypothesis of
geriatric memory dysfunction. Science 217, 408e414.
Buckner, R.L., Snyder, A.Z., Shannon, B.J., LaRossa, G., Sachs, R., Fotenos, A.F.,
Sheline, Y.I., Klunk, W.E., Mathis, C.A., Morris, J.C., Mintun, M.A., 2005. Molec-
ular, structural, and functional characterization of Alzheimer’s disease: evidence
for a relationship between default activity, amyloid, and memory. J. Neurosci.
25, 7709e7717.
Burnham, K.P., Anderson, D.R., 2002. Model Selection and Multimodel Inference.
Springer Verlang, New York.
Colloby, S.J., Firbank, M.J., Pakrasi, S., Lloyd, J.J., Driver, I., McKeith, I.G., Williams, E.D.,
O’Brien, J.T., 2008. A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT
imaging in the differential diagnosis of Alzheimer’s disease and dementia with
Lewy bodies. Int. Psychogeriatr. 20, 1124e1140.
Colloby, S.J., McKeith, I.G., Wyper, D.J., O’Brien, J.T., Taylor, J.P., 2015. Regional
covariance of muscarinic acetylcholine receptors in Alzheimer’s disease using
(R, R) [(123)I]-QNB SPECT. J. Neurol. 262, 2144e2153.
Cummings, J.L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D.A.,
Gornbein, J., 1994. The Neuropsychiatric Inventory: comprehensive assessment
of psychopathology in dementia. Neurology 44, 2308e2314.
Davies, P., Maloney, A.J., 1976. Selective loss of central cholinergic neurons in
Alzheimer’s disease. Lancet 2, 1403.
Dennis, E.L., Thompson, P.M., 2014. Functional brain connectivity using fMRI in
aging and Alzheimer’s disease. Neuropsychol. Rev. 24, 49e62.
Folstein, M.F., Folstein, S.E., McHugh, P.R., 1975. “Mini-mental state”. A practical
method for grading the cognitive state of patients for the clinician. J. Psychiatr.
Res. 12, 189e198.
Greicius, M.D., Srivastava, G., Reiss, A.L., Menon, V., 2004. Default-mode network
activity distinguishes Alzheimer’s disease from healthy aging: evidence from
functional MRI. Proc. Natl. Acad. Sci. U. S. A. 101, 4637e4642.
Habeck, C., Foster, N.L., Perneczky, R., Kurz, A., Alexopoulos, P., Koeppe, R.A.,
Drzezga, A., Stern, Y., 2008. Multivariate and univariate neuroimaging bio-
markers of Alzheimer’s disease. Neuroimage 40, 1503e1515.
Habeck, C., Krakauer, J.W., Ghez, C., Sackeim, H.A., Eidelberg, D., Stern, Y.,
Moeller, J.R., 2005. A new approach to spatial covariance modeling of functional
brain imaging data: ordinal trend analysis. Neural Comput. 17, 1602e1645.
Habeck, C., Stern, Y. Alzheimer’s Disease Neuroimaging Initiative, 2010. Multivariate
data analysis for neuroimaging data: overview and application to Alzheimer’s
disease. Cell Biochem. Biophys. 58, 53e67.
Hasselmo, M.E., 2006. The role of acetylcholine in learning and memory. Curr. Opin.
Neurobiol. 16, 710e715.
He, Y., Chen, Z., Gong, G., Evans, A., 2009. Neuronal networks in Alzheimer’s disease.
Neuroscientist 15, 333e350.
Himmelheber, A.M., Sarter, M., Bruno, J.P., 2000. Increases in cortical acetylcholine
release during sustained attention performance in rats. Brain Res. Cogn. Brain
Res. 9, 313e325.
Johnson, K.A., Jones, K., Holman, B.L., Becker, J.A., Spiers, P.A., Satlin, A., Albert, M.S.,
1998. Preclinical prediction of Alzheimer’s disease using SPECT. Neurology 50,
1563e1571.
Jones, B.F., Barnes, J., Uylings, H.B., Fox, N.C., Frost, C., Witter, M.P., Scheltens, P.,
2006. Differential regional atrophy of the cingulate gyrus in Alzheimer disease:
a volumetric MRI study. Cereb. Cortex 16, 1701e1708.
Klinkenberg, I., Sambeth, A., Blokland, A., 2011. Acetylcholine and attention. Behav.
Brain Res. 221, 430e442.
Lee, M.G., Hassani, O.K., Alonso, A., Jones, B.E., 2005. Cholinergic basal forebrain
neurons burst with theta during waking and paradoxical sleep. J. Neurosci. 25,
4365e4369.
S.J. Colloby et al. / Neurobiology of Aging 47 (2016) 83e9090Lim, M.M., Gerstner, J.R., Holtzman, D.M., 2014. The sleep-wake cycle and
Alzheimer’s disease: what do we know? Neurodegener. Dis. Manag. 4, 351e362.
Lindstrom, J., Anand, R., Peng, X., Gerzanich, V., Wang, F., Li, Y., 1995. Neuronal
nicotinic receptor subtypes. Ann. N. Y. Acad. Sci. 757, 100e116.
Markett, S., Reuter, M., Montag, C., Voigt, G., Lachmann, B., Rudorf, S., Elger, C.E.,
Weber, B., 2014. Assessing the function of the fronto-parietal attention network:
insights from resting-state fMRI and the attentional network test. Hum. Brain
Mapp. 35, 1700e1709.
McGaughy, J., Everitt, B.J., Robbins, T.W., Sarter, M., 2000. The role of cortical
cholinergic afferent projections in cognition: impact of new selective immu-
notoxins. Behav. Brain Res. 115, 251e263.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., 1984.
Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work
Group under the auspices of Department of Health and Human Services Task
Force on Alzheimer’s Disease. Neurology 34, 939e944.
Menon, V., Uddin, L.Q., 2010. Saliency, switching, attention and control: a network
model of insula function. Brain Struct. Funct. 214, 655e667.
O’Brien, J.T., Colloby, S.J., Pakrasi, S., Perry, E.K., Pimlott, S.L., Wyper, D.J.,
McKeith, I.G., Williams, E.D., 2007. Alpha4beta2 nicotinic receptor status in
Alzheimer’s disease using 123I-5IA-85380 single-photon-emission computed
tomography. J. Neurol. Neurosurg. Psychiatry 78, 356e362.
Papez, J.W., 1937. A proposed mechanism of emotion. Arch. Neurol. Psychiatry 38,
725e743.
Petersen, R.C., 1977. Scopolamine induced learning failures in man. Psychophar-
macology (Berl) 52, 283e289.
Raichle, M.E., MacLeod, A.M., Snyder, A.Z., Powers, W.J., Gusnard, D.A., Shulman, G.L.,
2001. A default mode of brain function. Proc. Natl. Acad. Sci. U. S. A. 98,
676e682.
Rosenberg, P.B., Nowrangi, M.A., Lyketsos, C.G., 2015. Neuropsychiatric symptoms in
Alzheimer’s disease: what might be associated brain circuits? Mol. Aspects Med.
43-44, 25e37.
Roth, M., Tym, E., Mountjoy, C.Q., Huppert, F.A., Hendrie, H., Verma, S.,
Goddard, R., 1986. CAMDAX a standardised instrument for the diagnosis of
mental disorder in the elderly with special reference to the early detection of
dementia. Br. J. Psychiatry 149, 698e709.Sarter, M., Paolone, G., 2011. Deficits in attentional control: cholinergic mechanisms
and circuitry-based treatment approaches. Behav. Neurosci. 125, 825e835.
Scarmeas, N., Habeck, C.G., Zarahn, E., Anderson, K.E., Park, A., Hilton, J., Pelton, G.H.,
Tabert, M.H., Honig, L.S., Moeller, J.R., Devanand, D.P., Stern, Y., 2004. Covariance
PET patterns in early Alzheimer’s disease and subjects with cognitive impair-
ment but no dementia: utility in group discrimination and correlations with
functional performance. Neuroimage 23, 35e45.
Seeley, W.W., Crawford, R.K., Zhou, J., Miller, B.L., Greicius, M.D., 2009. Neurode-
generative diseases target large-scale human brain networks. Neuron 62,
42e52.
Seeley, W.W., Menon, V., Schatzberg, A.F., Keller, J., Glover, G.H., Kenna, H., Reiss, A.L.,
Greicius, M.D., 2007. Dissociable intrinsic connectivity networks for salience
processing and executive control. J. Neurosci. 27, 2349e2356.
Simic, G., Babic, M., Borovecki, F., Hof, P.R., 2014. Early failure of the default-mode
network and the pathogenesis of Alzheimer’s disease. CNS Neurosci. Ther. 20,
692e698.
Smith, A.D., 2002. Imaging the progression of Alzheimer pathology through the
brain. Proc. Natl. Acad. Sci. U. S. A. 99, 4135e4137.
Sperling, R.A., Dickerson, B.C., Pihlajamaki, M., Vannini, P., LaViolette, P.S.,
Vitolo, O.V., Hedden, T., Becker, J.A., Rentz, D.M., Selkoe, D.J., Johnson, K.A., 2010.
Functional alterations in memory networks in early Alzheimer’s disease. Neu-
romolecular Med. 12, 27e43.
Whitehouse, P.J., Price, D.L., Struble, R.G., Clark, A.W., Coyle, J.T., Delon, M.R., 1982.
Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain.
Science 215, 1237e1239.
Xie, C., Bai, F., Yu, H., Shi, Y., Yuan, Y., Chen, G., Li, W., Chen, G., Zhang, Z., Li, S.J., 2012.
Abnormal insula functional network is associated with episodic memory
decline in amnestic mild cognitive impairment. Neuroimage 63, 320e327.
Zemek, F., Drtinova, L., Nepovimova, E., Sepsova, V., Korabecny, J., Klimes, J., Kuca, K.,
2014. Outcomes of Alzheimer’s disease therapy with acetylcholinesterase in-
hibitors and memantine. Expert Opin. Drug Saf. 13, 759e774.
Zhang, Z., Zheng, H., Liang, K., Wang, H., Kong, S., Hu, J., Wu, F., Sun, G., 2015.
Functional degeneration in dorsal and ventral attention systems in amnestic
mild cognitive impairment and Alzheimer’s disease: an fMRI study. Neurosci.
Lett. 585, 160e165.
